Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 22, 2017 – The FDA approved Celgene’s Revlimid (lenalidomide) for multiple myeloma (MM), as maintenance treatment following autologous hematopoietic stem cell transplantation (auto-HSCT).
Return to publications